| 1 |
30381648 | [A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan]. | 2018 |
1 |
| 2 |
23329590 | Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal. | 2013 Jan |
1 |
| 3 |
23679326 | Prognostic and predictive value of hematologic parameters in patients with metastatic renal cell carcinoma: second line sunitinib treatment following IFN-alpha. | 2013 |
1 |
| 4 |
23819366 | [Case of multiple lung metastases of renal cell carcinoma failing to respond to Interferon-alpha (IFN-alpha) and sunitinib but markedly responding to everolimus]. | 2013 May |
1 |
| 5 |
21265994 | Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. | 2011 Sep |
1 |
| 6 |
21704235 | Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis. | 2011 Jun |
1 |
| 7 |
19127560 | A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. | 2009 Feb 15 |
1 |
| 8 |
19213665 | Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. | 2009 Jan |
1 |
| 9 |
19568242 | Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness. | 2009 Jul 21 |
1 |
| 10 |
18366295 | Improving outcomes in patients with advanced renal cell carcinoma. | 2008 Mar |
2 |
| 11 |
18711190 | Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. | 2008 Aug 20 |
2 |
| 12 |
17621562 | Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma. | 2007 Mar |
1 |